Search Results - "Lemonnier, J."

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer by Cottu, P., D'Hondt, V., Dureau, S., Lerebours, F., Desmoulins, I., Heudel, P.-E., Duhoux, F.P., Levy, C., Mouret-Reynier, M.-A., Dalenc, F., Frenel, J.-S., Jouannaud, C., Venat-Bouvet, L., Nguyen, S., Ferrero, J.-M., Canon, J.-L., Grenier, J., Callens, C., Gentien, D., Lemonnier, J., Vincent-Salomon, A., Delaloge, S.

“…Palbociclib is a CDK4/6 inhibitor with demonstrated efficacy and safety in combination with endocrine therapy in advanced luminal breast cancer (LBC). We…”
Get full text

Activation of p38 Mitogen‐Activated Protein Kinase and c‐Jun‐NH2‐Terminal Kinase by BMP‐2 and Their Implication in the Stimulation of Osteoblastic Cell Differentiation by Guicheux, J, Lemonnier, J, Ghayor, C, Suzuki, A, Palmer, G, Caverzasio, J

“…Signaling involved in osteoblastic cell differentiation remains largely unknown. This study further investigates mechanisms involved in BMP‐2‐induced…”
Get full text

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab by Pierga, J.-Y., Bidard, F.-C., Autret, A., Petit, T., Andre, F., Dalenc, F., Levy, C., Ferrero, J.-M., Romieu, G., Bonneterre, J., Lerebours, F., Bachelot, T., Kerbrat, P., Campone, M., Eymard, J.-C., Mouret-Reynier, M.-A., Gligorov, J., Hardy-Bessard, A.-C., Lortholary, A., Soulie, P., Boher, J.-M., Proudhon, C., Charafe-Jaufret, E., Lemonnier, J., Bertucci, F., Viens, P.

“…We present a pooled analysis of predictive and prognostic values of circulating tumour cells (CTC) and circulating endothelial cells (CEC) in two prospective…”
Get full text

START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306) by Bonnefoi, H., Levy, C., MacGrogan, G., Grellety, T., Asselain, B., Pulido, M., Everhard, S., Lemonnier, J., Gonçalves, A.

Get full text

Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions by Bonerandi, J.J., Beauvillain, C., Caquant, L., Chassagne, J.F., Chaussade, V., Clavère, P., Desouches, C., Garnier, F., Grolleau, J.L., Grossin, M., Jourdain, A., Lemonnier, J.Y., Maillard, H., Ortonne, N., Rio, E., Simon, E., Sei, J.F., Grob, J.J., Martin, L.

Get full text

Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG) by Huober, J., Ribi, K., Weder, P., Li, Q., Vanlemmens, L., Gerard, M.-A., Lemonnier, J., Thürlimann, B., Boven, E., Bonnefoi, H.

Get full text

PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207) by Huober, J., Weder, P., Veyret, C., Thürlimann, B., Xyrafas, A., Vanlemmens, L., Guiu, S., Brain, E., Grenier, J., Dalenc, F., Levy, C., Savoye, A.M., Müller, A., Membrez-Antonioli, V., Gerard, M.A., Lemonnier, J., Hawle, H., Boven, E., Bonnefoi, H.

Get full text

Weight loss, physical and psychological patient reported outcomes (PROs) among obese patients (pts) with early breast cancer (BC) by Di Meglio, A., El-Mouhebb, M., Michiels, S., Jones, L., Martin, E., Matias, M., Lohmann Palhares, A.E., Joly, F., Vanlemmens, L., Everhard, S., Martin, A.L., Lemonnier, J., Arveux, P., Cottu, P.H., Coutant, C., Del Mastro, L., Partridge, A.H., André, F., Ligibel, J.A., Vaz-Luis, I.

Get full text

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel–5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer by Gonçalves, A., Pierga, J.-Y., Ferrero, J.-M., Mouret-Reynier, M.-A., Bachelot, T., Delva, R., Fabbro, M., Lerebours, F., Lotz, J.-P., Linassier, C., Dohollou, N., Eymard, J.-C., Leduc, B., Lemonnier, J., Martin, A.-L., Boher, J.-M., Viens, P., Roché, H.

“…Inflammatory breast cancer (IBC) is a rare and aggressive disease requiring a multimodal treatment. We evaluated the benefit of adding docetaxel–5-fluorouracil…”
Get full text

Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial by Penault-Llorca, F., Dalenc, F., Chabaud, S., Cottu, P., Allouache, D., Cameron, D., Grenier, J., Venat Bouvet, L., Jegannathen, A., Campone, M., Debled, M., Hardy-Bessard, A.-C., Giacchetti, S., Barthelemy, P., Kaluzinski, L., Mailliez, A., Mouret-Reynier, M.-A., Legouffe, E., Cayre, A., Martinez, M., Delbaldo, C., Mollon-Grange, D., Macaskill, E.J., Sephton, M., Stefani, L., Belgadi, B., Winter, M., Orfeuvre, H., Lacroix-Triki, M., Bonnefoi, H., Bliss, J., Canon, J.-L., Lemonnier, J., Andre, F., Bachelot, T.

“…The purpose of this study was to evaluate the prognostic value of the multigene EndoPredict test in prospectively collected data of patients screened for the…”
Get full text

Fibroblast growth factor-2 induces osteoblast survival through a phosphatidylinositol 3-kinase-dependent, -β-catenin-independent signaling pathway by Debiais, F, Lefèvre, G, Lemonnier, J, Le Mée, S, Lasmoles, F, Mascarelli, F, Marie, P.J

“…Fibroblast growth factor-2 (FGF-2) is an important molecule that controls bone formation through activation of osteoblastic cell replication and…”
Get full text

Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome by Lomri, A, Lemonnier, J, Hott, M, de Parseval, N, Lajeunie, E, Munnich, A, Renier, D, Marie, P J

“…Apert syndrome, associated with fibroblast growth factor receptor (FGFR) 2 mutations, is characterized by premature fusion of cranial sutures. We analyzed…”
Get full text

Fibroblast growth factor-2 (FGF-2) increases N-cadherin expression through protein kinase C and Src-kinase pathways in human calvaria osteoblasts by Debiais, Françoise, Lemonnier, Jérome, Hay, Eric, Delannoy, Philippe, Caverzasio, Joseph, Marie, Pierre J

“…Fibroblast growth factors (FGFs) are important factors regulating osteogenesis. However, the early mechanisms and signaling pathways involved in FGF actions in…”
Get full text

Increased Expression of Protein Kinase Cα, Interleukin‐1α, and RhoA Guanosine 5′‐Triphosphatase in Osteoblasts Expressing the Ser252Trp Fibroblast Growth Factor 2 Apert Mutation: Identification by Analysis of Complementary DNA Microarray by Lomri, Abderrahim, Lemonnier, Jérome, Delannoy, Philippe, Marie, Pierre J.

“…Apert (Ap) syndrome is a craniofacial malformation characterized by premature fusion of cranial sutures (craniosynostosis). We previously showed that the…”
Get full text

The Ser252Trp Fibroblast Growth Factor Receptor-2 (FGFR-2) Mutation Induces PKC-Independent Downregulation of FGFR-2 Associated with Premature Calvaria Osteoblast Differentiation by Lemonnier, J., Delannoy, Ph, Hott, M., Lomri, A., Modrowski, D., Marie, P.J.

“…We recently showed that the Apert Ser252Trp fibroblast growth factor receptor-2 (FGFR-2) mutation causes premature osteoblast differentiation and increased…”
Get full text

The Nearby Supernova Factory by Wood-Vasey, W.M., Aldering, G., Lee, B.C., Loken, S., Nugent, P., Perlmutter, S., Siegrist, J., Wang, L., Antilogus, P., Astier, P., Hardin, D., Pain, R., Copin, Y., Smadja, G., Gangler, E., Castera, A., Adam, G., Bacon, R., Lemonnier, J.-P., Pécontal, A., Pécontal, E., Kessler, R.

“…The Nearby Supernova Factory (SNfactory) is an ambitious project to find and study in detail approximately 300 nearby Type Ia supernovae (SNe Ia) at redshifts…”
Get full text

1ISG-027 Carbon footprint of a sterilisation unit by Lemonnier, J, Talon, D

“…Background and importancePreparation of the Greenhouse Gas Emission Balance (GGEB) has become mandatory in hospitals but is not yet carried out in healthcare…”
Get full text

Bone Morphogenetic Protein-2 Promotes Osteoblast Apoptosis through a Smad-independent, Protein Kinase C-dependent Signaling Pathway by Hay, E, Lemonnier, J, Fromigue, O, Marie, P J

“…Bone morphogenetic protein-2 (BMP-2), a member of the transforming growth factor-β (TGF-β) family, regulates osteoblast differentiation and bone formation…”
Get full text

Cbl-mediated Degradation of Lyn and Fyn Induced by Constitutive Fibroblast Growth Factor Receptor-2 Activation Supports Osteoblast Differentiation by Kaabeche, Karim, Lemonnier, Jérome, Le Mée, Sandrine, Caverzasio, Joseph, Marie, Pierre J

“…Fibroblast growth factors (FGFs) play an important regulatory role in skeletal development and bone formation. However, the FGF signaling mechanisms…”
Get full text

Protein Kinase C-Dependent Upregulation of N-Cadherin Expression by Phorbol Ester in Human Calvaria Osteoblasts by Delannoy, Ph, Lemonnier, J., Haÿ, E., Modrowski, D., Marie, P.J.

“…Cell–cell adhesion mediated by cadherins is believed to play an essential role in the control of cell differentiation and tissue formation. Our recent studies…”
Get full text